Table 2 The main clinical features in CMV-detected groups.

Age

1-110 months

2-164 months

4-163 months

   1-12 months

7 (28.0%)

22 (21.2%)

12 (30.6%)

   12-36 months

8 (32.0%)

36 (34.6%)

11 (36.1%)

   36-72 months

6 (24.0%)

25 (24.0%)

6 (16.7%)

   > 72 months

4 (16.0%)

21 (20.2%)

6 (16.7%)

Sex, male/female

17/8

65/39

24/12

Length of stay, days

13.04 ± 4.16*

8.26 ± 3.07**

8.28 ± 4.14**

Duration of fever, days

5.36 ± 4.32

4.96 ± 4.38

6.03 ± 5.11

Fever

20 (80.0%)

82 (78.8%)

29 (80.6%)

Rash

1 (4.00%)*

24 (23.1%)**

7 (19.4%)**

Lymphadenopathy

13 (52.0%)

37 (35.6%)

9 (25%)

Pharyngitis

23 (92.0%)

101 (97.1%)

34 (94.4%)

Palatal petechiae

10 (40.0%)*

16 (15.4%)**

2 (5.56%)**

Hepatomegaly

13 (52.0%)*

12 (11.5%)**

2 (5.56%)**

Splenomegaly

8 (32.0%)*

3 (2.88%)**

1 (2.78%)**

ALC > 10%

12/16 (75.0%)*

12/58 (20.7%)**

4/14 (28.6%)**

Elevated ESR

8/14 (57.1%)

35/61 (57.4%)

13/21 (61.9%)

CRP > 10 mg/L

8/15 (53.3%)

33/61 (54.1%)

16/22 (72.7%)

ALF

15/21 (71.4%)*

9/37 (24.3%)**

3/13 (23.1%)**

WBC count, 10⁹/L

14.42 ± 8.31

11.07 ± 15.72

9.07 ± 6.14

Neutrophils, %

24.15 ± 15.70*

43.60 ± 23.3**

39.44 ± 25.90**

Lymphocytes, %

62.03 ± 16.74*

44.79 ± 22.39**

48.92 ± 25.57**

Monocytes, %

10.63 ± 5.81

9.89 ± 6.36

9.63 ± 4.90

Platelets, 10⁹/L

253.96 ± 96.02

304.72 ± 143.25

305.97 ± 121.85

Hemoglobin, g/L

113.30 ± 9.91

118.59 ± 11.92

118.35 ± 12.26